Author

Daud D Peter

Observed names: Daud D. Peter, Daud Dunstan Peter, Daud Peter

Institution: Aurum Institute

Observed institution: Aurum Institute

OpenAlex ID: A5015501571

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

2025 · Norbert Heinrich, Norbert Heinrich, et al. · The Lancet Infectious Diseases · 20

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

2025 · Lilian Tina Minja, Isabella van der Feltz, et al. · The Lancet Infectious Diseases · 18

Project Extension for Community Healthcare Outcomes Improves Care and Treatment for Multidrug-Resistant Tuberculosis Patients in Tanzania

2021 · Daud Dunstan Peter, Shabani Ramadhani Mziray, et al. · International Journal of Mycobacteriology · 7

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5

Usefulness of IPC ECHO Clinic in Tanzania—Experience from Its Evaluation in 10 Referral Hospitals

2025 · Ruth R. Ngowi, Stephano S. Simba, et al. · Health · 1

A Prospective, Randomised, Open Label Phase 2b Dose-Finding Trial of Delpazolid in Combination with Bedaquiline, Delamanid and Moxifloxacin for Pulmonary Tuberculosis: DECODE

2024 · Lilian Tina Minja, Isabella van der Feltz, et al. · SSRN Electronic Journal

Works count: 6

Citation count: 51

H-index: 4

I10-index: 2